Literature DB >> 7346041

Prevention of syngeneic tumor growth in vaccinia virus-primed mice by immunization with vaccinia virus-modulated tumor cells.

K S Wu, S Ueda, Y Sakaue, Y Ohashi, K Ikuta, T Sugano, S Kato.   

Abstract

Immunization with vaccinia virus-infected and then X-ray-irradiated murine hepatoma MH134 cells provided C3H/He mice with strong resistance to challenge with viable MH134 cells. Male C3H/He mice of 5 to 6 weeks old were primed intraperitoneally (IP) with 1 x 10(7) PFU of live vaccinia virus (Ikeda strain) after irradiation with 250 R of X-ray. Three weeks after priming, the mice were immunized IP 3 times at weekly intervals with 1 x 10(7) X-ray-irradiated MH134 cells that had been infected with vaccinia virus 8 h before irradiation. Over 60% of these cells showed vaccinia virus-induced antigen on their surface (membrane antigen). Challenge with viable MH134 cells was done by inoculating 1 x 10(5) cells IP one week after immunization. During a 4-week observation period, all the untreated control mice died with ascites. On the contrary, all the mice that were X-ray-irradiated, primed and immunized survived challenge with the tumor cells for at least 4 weeks. The mortalities of mice in other groups that were not irradiated, or not primed, or immunized with only X-ray-irradiated tumor cells, were at lowest 50%.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7346041

Source DB:  PubMed          Journal:  Biken J        ISSN: 0006-2324


  5 in total

1.  Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.

Authors:  T P Archer; P Bretscher; B Ziola
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

2.  Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

Authors:  R J Natuk; J A Byrne; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.

Authors:  N Wakamiya; Y L Wang; H Imai; H X Gu; S Ueda; S Kato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 4.  Oncolytic viruses.

Authors:  J Nemunaitis
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

5.  Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement.

Authors:  N Wakamiya; N Okada; Y L Wang; T Ito; S Ueda; S Kato; H Okada
Journal:  Jpn J Cancer Res       Date:  1989-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.